Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection

Enferm Infecc Microbiol Clin. 2015 Jan;33(1):41-7. doi: 10.1016/j.eimc.2014.05.018. Epub 2014 Aug 3.

Abstract

The importance of the metabolic disorders and their impact on patients with HIV infection requires an individualized study and continuous updating. HIV patients have the same cardiovascular risk factors as the general population. The HIV infection per se increases the cardiovascular risk, and metabolic disorders caused by some antiretroviral drugs are added risk factors. For this reason, the choice of drugs with a good metabolic profile is essential. The most common metabolic disorders of HIV infected-patients (insulin resistance, diabetes, hyperlipidemia or osteopenia), as well as other factors of cardiovascular risk, such as hypertension, should also be dealt with according to guidelines similar to the general population, as well as insisting on steps to healthier lifestyles. The aim of this document is to provide a query tool for all professionals who treat HIV-patients and who may present or display any metabolic disorders listed in this document.

Keywords: Alteraciones metabólicas; Cardiovascular risk; HIV infection; Infección por VIH; Metabolic disorders; Riesgo cardiovascular.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / prevention & control
  • Comorbidity
  • Exercise
  • HIV Infections / epidemiology*
  • Health Promotion
  • Healthy Lifestyle
  • Humans
  • Lipid Metabolism Disorders / chemically induced
  • Lipid Metabolism Disorders / epidemiology
  • Metabolic Diseases / chemically induced
  • Metabolic Diseases / epidemiology*
  • Metabolic Diseases / therapy
  • Risk Factors
  • Sexual Dysfunction, Physiological / epidemiology
  • Sexual Dysfunction, Physiological / etiology
  • Smoking Cessation

Substances

  • Anti-HIV Agents